Now The company has RSI figure of 55.56. RSI compares the magnitude of recent gains to recent losses to see if an asset is oversold or overbought. RSI is plotted on a scale of 0-100. Generally, if it is above 70, the stock is considered overbought and so one can look to sell it. Similarly, an RSI of less than 30 indicates the stock is oversold and can be bought.
ADX value listed at 26.57. The ADX indicator measures the strength of a trend and can be useful to determine if a trend is strong or weak. High readings indicate a strong trend and low readings indicate a weak trend. When this indicator is showing a low reading then a trading range is likely to develop. Avoid stocks with low readings! You want to be in stocks that have high readings. This indicator stands for Average Directional Index. On some charting packages there are two other lines on the chart, +DI and -DI (the DI part stands for Directional Indicator). Ignore these lines. Trying to trade according to these two lines is a great way to lose money! The only thing that we are concerned with is the ADX itself.
Sorrento Therapeutics (NASDAQ:SRNE) has performed 0.4144% around last month and performed -0.3679% over the last quarter. The stock showed return of -0.714% over five years and registered weekly return of 0.1228%. The stock has been watched at -0.321% return throughout last twelve months.
Tracking last 52 weeks, the stock 52 week high price observed at $5 +98.83% and 52 week low seen at $1 -45.70%. The 50 SMA is $2 +15.64% and 200 SMA is $3 -3.72%. Moving averages can be used as support or resistance when a trader looks for a possible entry or exit in the market. This can also be said in the following way. In case the price makes a contact with the moving average on the price chart, the trader, examining closely this chart, will enter either into a long, or into a short position. Actually, this works in the same way as horizontal support or resistance lines. Moving averages are known as dynamic support and resistance, simply because they tend to change with prices.
Sorrento Therapeutics (NASDAQ:SRNE) stock has changed -0.01 and moved -0.0039% whereas stock price touched at 2.56 in last trading period. 4249360 shares exchanged at hands while it’s an average volume stands with 6.165M shares. The company recorded relative volume of 0.69 ×. Volume indicators are popular tools among traders because they can help confirm whether other investors agree with your perspective on a security. Traders generally watch for the volume to increase as an identified trend gains momentum. Large spikes suggest that the stock has garnered much attention from the trading community and that the shares are under either accumulation or distribution. A sudden decrease in volume can suggest that traders are losing interest and that a reversal may be on its way.
Analyst recommended consensus rating of 1 on this stock. Analysts also expected that stock to achieve share value at $24 +837.50% in coming one year period. EBITDA is -$180.140M. EBITDA is a company’s earnings before interest, taxes, depreciation, and amortization and is an accounting measure calculated using a company’s net earnings, before interest expenses, taxes, depreciation and amortization are subtracted, as a proxy for a company’s current operating profitability.
The company made Revenue of $31.432M. Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time. Net Income of the company is -$292.068M. Net Income Available for Common Shareholders equals net income minus preferred dividends paid. Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders’ claim on the company’s cash flows.
Return on capital employed (ROCE) is -0.5795%. Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used. Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders’ equity and debt liabilities. It can be simplified as total assets minus current liabilities.
The current ratio is 0.59. The current ratio is the classic measure of liquidity. It indicates whether the business can pay debts due within one year out of the current assets. The quick ratio is 0.56. 1:1 shows the business can meet its current financial obligations with quick funds on hand. A ratio lower than 1:1 may indicate that the company relies too much on inventory or other assets to pay its short-term liabilities.
The debt/equity shows a value of 6.68. D/E Ratio is calculated by dividing a company’s total liabilities by its shareholder equity. In general, a high debt-to-equity ratio indicates that a company may not be able to generate enough cash to satisfy its debt obligations. However, low debt-to-equity ratios may also indicate that a company is not taking advantage of the increased profits that financial leverage may bring.
Volatility or average true range percent (ATRP 14) is 0.1003%. The ATR expressed as a percentage of closing price. Average true range percent (ATRP) measures volatility on a relative level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won’t necessarily have lower ATR values than higher-priced stocks. The stock beta value watched at 0.46. Beta measures the amount of market risk associated with market trade. High beta reveals more riskiness and low beta shows low risk.
Tracking profitability check, the firm profit margin which was recorded at -929.21% and operating margin noted at -825.25%. The company maintained a Gross Margin of 61.07%. The Institutional ownership of the firm is 17.74% while Insiders ownership is 34.21%. The Company has been able to maintain return on asset (ROA) at -50.46% for the last twelve months. Return on equity (ROE) recorded at -343.65%.
Sorrento Therapeutics (NASDAQ:SRNE)’s stock has P/S ratio of 13.15 reflects the value placed on sales by the market. P/B ratio is 5.26. P/B is used to compare a stock’s market value to its book value. It has a market cap of $413.46M. Using market capitalization to show the size of a company is important because company size is a basic determinant of various characteristics in which investors are interested, including risk.